Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Half Yearly Report

13 Feb 2015 07:00

RNS Number : 8129E
Feedback PLC
13 February 2015
 

FEEDBACK PLC

 

Feedback plc

("Feedback", the "Company" or the "Group")

 

Interim Report for the six months ended 30 November 2014

 

Chairman's Statement

 

We are pleased to present the results for the six months ended 30 November 2014. This is the first set of results that includes the trading of the two medical imaging companies, Cambridge Computed Imaging Limited ('CCI') and TexRAD Limited, (TexRAD) acquired in May 2014.

 

Revenue for the six month period was £229,000 (2013: non trading) and the loss after tax was £219,000. (2013: loss of £471,000). The loss before interest, tax and amortisation was £138,000 (2013: Loss £471,000). The cash balance at 30 November 2014 was £268,000, (2013: £696,000) which was after the payment of certain overdue creditors totalling £189,000 owed by CCI.

 

During this period, significant progress has been made with CCI achieving ISO 13485, the International Standard relating to quality management systems for organisations involved in the manufacture of medical devices.

 

TexRAD has been granted a European patent. The Group continues to make progress towards the launch later this year of a commercial version of its TexRAD software for the pharmaceutical trials market which is expected to be achieved following 21 CFR 11 self certification in the second quarter of 2015. We will continue to work with our distributor to gain momentum in this market.

 

The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015.

 

The Group has invested in people over the period. Two new staff were appointed during the six months under review, with a further two joining before the year end to prepare the business for commercial sales of the products.

 

We continue to look to develop the Group's presence in the medical imaging sector through acquisitions and collaborations with research institutions. We can offer software systems and regulatory assistance for new medical imaging techniques which will assist the process of bringing them to market.

 

2015 is expected to be a year of transition for the Company as it moves from development to commercialisation with its TexRAD product.

 

Simon Barrell

Chairman

 

 

Enquiries:

Feedback plc

Simon Barrell

Tom Charlton

Trevor Brown

 

Tel: 01954 718072

Sanlam Securities UK Limited (Nominated adviser)

Simon Clements/Virginia Bull

 

Tel: 020 7628 2200

 

 

 

UNAUDITED CONSOLIDATED INCOME STATEMENT

 

 

6 months to

30 November 2014

6 months to

30 November 2013

Year to 31 May

2014

 

£'000

£'000

£'000

Revenue

229

-

7

Cost of sales

(42)

-

-

Gross profit

187

-

7

Other operating expenses

(415)

(114)

(314)

Costs associated with the acquisition of subsidiaries

 

-

 

-

 

(164)

Total operating expenses

(415)

(114)

(478)

Operating loss

(229)

(114)

(471)

Losses on disposal of discontinued operations

-

-

-

Finance costs

-

(8)

-

Loss before tax

(229)

(122)

(471)

Tax credit/(expense)

10

-

-

Loss for the period attributable to the equity shareholders of the parent Loss on ordinary activities after tax

 

 

(219)

 

 

(122)

 

 

(471)

Other comprehensive income/(expense)

Translation differences on overseas operations

 

-

 

(14)

 

(3)

Total comprehensive expense for the period

 

(219)

 (136)

 

(474)

Basic and diluted earnings per share

 

2

 

(0.011p)

 

(0.09p)

 

(0.27p)

 

 

 

 

 

UNAUDITED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 

 

Share Capital

Share Premium

Capital Reserve

Retained Earnings

Translation Reserve

Convertible Debt Option Reserve

Total

£'000

£'000

£'000

£'000

£'000

£'000

£'000

Balance at 31 May 2013

327

851

300

(510)

(207)

-

761

Total comprehensive income for the period

 

-

 

-

 

-

 

(122)

 

(14)

 

-

 

(136)

Balance at 30 November 2013

327

851

300

(632)

(221)

-

625

New shares issued

150

598

-

-

-

-

748

Costs associated with the raising of funds

 

-

 

(40)

 

-

 

-

 

-

 

-

 

(40)

Share option and warrant costs

-

-

14

-

-

14

Convertible debt raised in the year

-

-

-

-

-

189

189

Total comprehensive expense for the period

 

-

 

-

 

-

 

(349)

 

11

 

-

 

(338)

Balance at 31 May 2014

477

1,409

300

(967)

(210)

189

1,198

Share option and warrant costs

-

-

-

3

-

-

3

Total comprehensive income for the period

 

-

 

-

 

-

 

(219)

 

-

 

-

 

(219)

Balance at 30 November 2013

477

1,409

300

(1,183)

(210)

189

982

 

UNAUDITED CONSOLIDATED BALANCE SHEET

 

 

 

30 November 2014

30 November 2013

31 May

2014

 

£'000

£'000

£'000

ASSETS

 

Non-current assets

Property, plant and equipment

6

-

1

Intangible assets

839

-

848

 

 

845

-

849

 

Current assets

Trade receivables

160

-

87

Other receivables

73

17

121

Cash and cash equivalents

268

696

874

 

 

501

713

1,082

 

Total assets

1,346

713

1,931

 

 

EQUITY

 

Capital and reserves attributable to the Company's equity shareholders

Called up share capital

477

327

477

Share premium account

1,409

851

1,409

Capital reserve

300

300

300

Translation reserve

(210)

(221)

(210)

Retained earnings

(1,183)

(632)

(967)

 

798

625

1,009

Convertible debt option reserve

189

-

189

Total equity

982

625

1,197

 

LIABILITIES

 

Non-current liabilities

Deferred tax liabilities

70

-

80

 

Current liabilities

Trade payables

81

66

225

Other payables

213

22

428

 

 

294

88

653

 

Total liabilities

364

88

733

 

Net assets

1,346

625

1,931

 

 

 

 

 

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT

 

 

 

6 months to

30 November 2014

6 months to

30 November 2013

Year to

31 May

2014

 

£'000

£'000

£'000

 

Cash flows from operating activities

Loss before tax

(229)

(122)

(471)

Adjustments for:

Cost of acquisition of subsidiaries

-

164

Share option and warrant charges

3

-

-

Finance charges

-

8

-

Depreciation and amortisation

91

-

-

Foreign exchange difference

-

(14)

3

(Increase)/decrease in trade receivables

(72)

-

-

Decrease/(increase) in other receivables

49

(2)

(80)

(Decrease)/increase in trade payables

(145)

(36)

57

Decrease in other payables

(217)

(412)

(155)

 

 

(291)

(456)

(11)

 

Net cash used in operating activities

(520)

(578)

(482)

 

Cash flows from investing activities

Purchase of tangible fixed assets

(6)

-

-

Purchase of intangible assets

(80)

-

-

Proceeds from sale of assets held for resale

-

940

940

Cash received on purchase of subsidiaries

-

-

65

Cash paid on acquisition of subsidiaries

-

-

(31)

Cash on acquisition of subsidiaries including costs

-

-

(164)

 

Net cash (used in)/generated from investing activities

(86)

940

810

 

Cash flows from financing activities

Interest paid

-

(8)

-

Loan repayment

-

-

(245)

Equity based loan received

-

-

189

Net proceeds from share issue

-

-

260

 

Net cash generated from financing activities

-

(8)

204

 

 

Net movement in cash and cash equivalents

(606)

354

532

Cash and cash equivalents at beginning of period

874

342

342

 

Cash and cash equivalents at end of period

268

696

874

 

 

 

 

 

 

 

 

 

 

FEEDBACK PLC

 

NOTES TO THE UNAUDITED INTERIM REPORT

 

 

 

1. BASIS OF PREPARATION

 

The consolidated interim financial statements have been prepared in accordance with the recognition and measurement principles of International Financial Reporting Standards as endorsed by the European Union ("IFRS") and expected to be effective at the year end of 31 May 2015. The accounting policies are unchanged from the financial statements for the year ended 31 May 2014.

 

The information set out in this interim report for the six months ended 30 November 2014 does not comprise statutory accounts within the meaning of section 434 of The Companies Act 2006. The results for the period ended 31 May 2014 are based on the published accounts for that period on which the auditors gave a report which did not contain statements under section 498 of the Companies Act 2006. The accounts for the period ended 31 May 2014 have been filed with the Registrar of Companies.

 

This interim report was approved by the directors on 13 February 2014.

 

 

2 LOSS PER SHARE

.

Basic earnings per share is calculated by reference to the loss on ordinary activities after and on the weighted average of shares in issue.

As at 30 November 2014

 

As at 30 November 2013

 

As at 31 May 2014

 

£'000

£'000

£'000

Net loss attributable to ordinary equity holders

(219)

 

(122)

(471)

As at 30 November 2014

 

As at 30 November 2013

 

As at 31 May 2014

Weighted average number of ordinary shares for basic earnings per share

190,746,746

 

 

130,946,746

132,912,773

Effect of dilution:

Share Options

-

-

-

Warrants

-

-

-

Weighted average number of ordinary shares adjusted for the effect of dilution

190,746,746

 

 

130,946,746

132,912,773

Loss per share (pence)

Basic

(0.11)

(0.09)

(0.35)

 

 

 

 

3 INTANGIBLE ASSETS

Software

Customer relationships

Patents

Goodwill

Total

£'000

£'000

£'000

£'000

£'000

Cost

At 31 May 2013

-

-

-

-

-

Additions

-

-

-

-

-

Disposed on sale of subsidiary

-

-

-

-

-

-

-

-

-

-

At 30 November 2013

Additions

20

-

-

-

20

Acquired with subsidiary

415

100

41

272

828

At 31 May 2014

435

100

41

272

848

Additions

64

-

16

-

80

At 30 November 2014

499

100

57

272

928

Amortisation

At 31 May 2013

-

-

-

-

-

Charge for the period

-

-

-

-

-

-

-

-

-

-

At 30 November 2013

Charge for the period

-

-

-

-

-

At 31 May 2014

-

-

-

-

-

Charge for the period

73

13

4

-

90

As at 31 November 2014

73

13

4

-

90

Net Book Value

30 November 2014

426

87

53

272

838

At 31 May 2014

435

100

41

272

848

At 30 November 2013

-

-

-

-

-

 

 

4 AVAILABILITY OF THE INTERIM REPORT

Copies of the report will be available from the Company's office and also from the Company's website www.fbk.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR TTMTTMBABTIA
Date   Source Headline
19th Oct 20217:00 amRNSPilot Scheme with Sussex Integrated Care System
11th Oct 20217:00 amRNSMOU with Quest Teleradiology
29th Sep 20217:00 amRNSFeedback Joins NHS AI Procurement Framework
23rd Sep 20217:00 amRNSOfficial Launch of Bleepa Box
14th Sep 20217:00 amRNSMemorandum of Understanding with Qure.ai
9th Sep 20217:00 amRNSLaunch of CareLocker to enhance Bleepa technology
25th Aug 20217:00 amRNSChange of Adviser
3rd Aug 20217:00 amRNSDigital Health article highlights Bleepa potential
16th Jul 20217:00 amRNSBleepa agreement with CVS Equine Division
5th Jul 202110:17 amRNSHolding(s) in Company
30th Jun 20213:30 pmRNSBoard Update
29th Jun 20217:00 amRNSUK Medical Device Certification for Bleepa
10th Jun 20217:00 amRNSBleepa available on Apple App Store & Google Play
8th Jun 20217:00 amRNSYear End Trading Update
6th May 20217:00 amRNSExecutive Appointment
24th Mar 20217:00 amRNSRoyal Berkshire NHS Foundation Trust Contract
23rd Feb 20217:00 amRNSHalf-year Report
19th Jan 20217:00 amRNSBleepa builds on robust data management security
4th Dec 20207:00 amRNSBleepa to join DIT’s first virtual event to India
10th Nov 20209:06 amRNSSelected for Digitalhealth.London 2020 Programme
6th Nov 20203:03 pmRNSResult of Annual General Meeting - Amendment
6th Nov 20201:50 pmRNSHolding(s) in Company
5th Nov 20201:23 pmRNSResult of AGM
5th Nov 20207:01 amRNSBleepa selected for WISH 2020 Innovation Awards
5th Nov 20207:00 amRNSAGM Statement
28th Oct 20203:10 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSBleepa adds 3D Imaging with Axial3D Partnership
13th Oct 20207:00 amRNSFinal Results
26th Aug 20201:34 pmRNSHolding(s) in Company
7th Aug 20207:00 amRNSDirector/PDMR Shareholding
5th Aug 20204:36 pmRNSPrice Monitoring Extension
31st Jul 20205:00 pmRNSTotal Voting Rights
30th Jul 20203:48 pmRNSBleepa appointed to major NHSx framework
29th Jul 20202:06 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSAppointment of Non-Executive Director
10th Jul 20207:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 202011:01 amRNSHolding(s) in Company
6th Jul 202010:36 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 202012:46 pmRNSResult of Open Offer and General Meeting
25th Jun 202011:59 amRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSPlacing, Open Offer and Notice of GM
1st Jun 20207:00 amRNSBleepa® achieves CE Mark
21st May 20207:00 amRNSPapworth NHS Hosp - contract renewal with Bleepa
29th Apr 20202:05 pmRNSSecond Price Monitoring Extn
29th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.